Scientific Validation
Know Labs is advancing the testing of Bio-RFID, progressing on the path to FDA submission for clearance as a medical-grade device. As we prioritize external validation of our technology and transparency in our progress, we are continuously adding to a growing body of evidence.
Algorithm Refinement In The Non-Invasive Detection of Blood Glucose
May 30, 2023
Peer-Reviewed By: Members of Know Labs' Scientific Advisory Board
A study titled, “Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs’ Bio-RFID Technology.” demonstrates a machine learning model and other data science techniques improved the accuracy of Bio-RFID for predicting blood glucose, using the Dexcom G6® as reference device.
Dominic Klyve, Kaptain Currie, Carl Ward, David Schwarz, Barry Shelton (2023, May 25). Algorithm Refinement in the Non-Invasive Detection of Blood Glucose Using Know Labs’ Bio-RFID Technology.
Technical Feasibility Clinical Study
May 5, 2023
Peer-Reviewed By: American Association of Clinical Endocrinology
A study titled, “Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6®,” demonstrates that the Bio-RFID sensor can deliver stable, repeatable results in predicting blood glucose concentrations using the Dexcom G6® as a reference device. Results were presented at American Association of Clinical Endocrinology (AACE) 2023 Annual Meeting.
Dominic Klyve, Barry Shelton, Carl Ward, David Schwarz, James H. Anderson Jr., Steve Kent. (2023, May 5). Technical Feasibility of a Novel Sensor for Non-Invasive Blood Glucose Monitoring Compared to Dexcom G6®. American Association of Clinical Endocrinology, Seattle, WA.
Proof of Principle Study in Collaboration with Mayo Clinic
April 21, 2023
Peer-Reviewed By: Sensors Journal & American Physiology Society
A study titled, “Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions – Implications for Non-Invasive Physiologic Monitoring,” was conducted in collaboration with Mayo Clinic and demonstrates the accuracy of Know Labs’ non-invasive Bio-RFID technology in quantifying different analytes in vitro. Results were presented at the American Physiological Society 2023 Summit.
Klyve D, Anderson JH, Lorentz G, Somers VK. Detecting Unique Analyte-Specific Radio Frequency Spectral Responses in Liquid Solutions—Implications for Non-Invasive Physiologic Monitoring. Sensors. 2023;23(10):4817. doi:10.3390/s23104817
Proof of Concept Clinical Study
February 28, 2023
This technical report titled, "Non-Invasive Blood Glucose Monitoring: A Validation of a Novel Sensor Compared to a Dexcom G6®," presents proof of concept for a new method to quantify blood glucose levels (BGL) in vivo non-invasively using RF methods by means of training a model to predict readings of the Dexcom G6®, as a proxy for BGL. The method uses a new type of sensing device that rapidly scans a wide band of RF frequencies. The report outlines data science techniques used to train a neural network model to make predictions, and includes metrics of model success and future directions of this work.
Dominic Klyve, Barry Shelton, Steve Lowe, Carl Ward, David Schwarz, Steve Kent. (2023). Non-Invasive Blood Glucose Monitoring: A Validation of a Novel Sensor Compared to a Dexcom G6.
Peer-Reviewed By: Members of Know Labs' Scientific Advisory Board
Bio-RFID
Path to Market
Know Labs is advancing the testing of Bio-RFID, progressing on the path to FDA submission for clearance as a medical device.
Development Progress
Our clinical team collects thousands of data points each time a glucose test is performed. The Know Labs' team of data scientists uses this data to refine the algorithm that controls and enables Bio-RFID to identify and measure glucose.
Internal Trial - September 2022
We compared our benchtop prototype to the FDA-cleared Accu-Chek® and minimally invasive Dexcom®G6 and Freestyle Libre®. Our results are just as accurate or better. This is a big deal.